Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

  • Matthew Herper
  • Adam Feuerstein

By Matthew Herper and Adam Feuerstein Nov. 12, 2019

Reprints
Vascepa pill handout
Amarin

STAT will be providing regular updates throughout the day on Thursday’s FDA advisory committee meeting on Vascepa. For access, sign up for STAT Plus.

Amarin, exhale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Matthew Herper

Matthew Herper

Senior Writer, Medicine, Editorial Director of Events

Matthew Herper covers medical innovation — both its promise and its perils.

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

The history of OxyContin, told through unsealed Purdue documents
The history of OxyContin, told through unsealed Purdue documents
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
New research may give geneticists a long-sought tool: a…
New research may give geneticists a long-sought tool: a targeted protein delivery device
Under pressure, biotech and pharma grapple with how to…
Under pressure, biotech and pharma grapple with how to take climate action
Oscar Health names former Aetna executive as new CEO
Oscar Health names former Aetna executive as new CEO

Comments are closed.

Recommended Stories